Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark, with preliminary imaging data showing encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, which the company believes could enhance development of MS therapies including its investigational candidate Lucid-MS, for which an IND submission for a Phase 2 trial was submitted to the FDA in March 2026.
The milestone represents a significant step forward in the development of more precise diagnostic tools for multiple sclerosis. Current imaging methods, such as MRI, have limitations in detecting gray matter lesions and acute demyelination. The [¹⁸F]3F4AP tracer, a positron emission tomography (PET) radioligand, targets potassium channels exposed during demyelination, potentially offering a direct measure of myelin loss. If validated, this technique could provide a biomarker for disease activity and treatment response, addressing a critical unmet need in MS clinical trials.
For Quantum BioPharma, the study's success could de-risk the development of Lucid-MS, a patented new chemical entity that has shown ability to prevent and reverse myelin degradation in preclinical models. The company submitted an Investigational New Drug (IND) application for a Phase 2 trial of Lucid-MS in March 2026, building on earlier clinical data. The imaging study, conducted in collaboration with Massachusetts General Hospital, aims to establish a non-invasive method to quantify demyelination, which could serve as a surrogate endpoint in future trials.
The implications extend beyond MS. The [¹⁸F]3F4AP tracer could potentially be applied to other demyelinating conditions, such as neuromyelitis optica or transverse myelitis. Moreover, the ability to visualize myelin repair in real time could accelerate the development of remyelinating therapies across neurodegenerative diseases.
Quantum BioPharma is also advancing other assets, including UNBUZZD, an over-the-counter product for alcohol misuse, through its stake in Unbuzzd Wellness Inc. The company retains a 19.84% ownership in Unbuzzd and receives royalty payments of 7% of sales until $250 million, then 3% in perpetuity. However, the focus remains on the MS imaging study and Lucid-MS, which represent the core of Quantum's pipeline.
The full press release is available at https://ibn.fm/4IZ0y. For the latest news and updates on Quantum BioPharma, visit the company's newsroom at https://ibn.fm/QNTM.
This announcement underscores the growing convergence of advanced imaging and targeted therapeutics in neurology. If the [¹⁸F]3F4AP tracer proves effective, it could become a standard tool in MS clinical trials, improving the efficiency of drug development and ultimately leading to better outcomes for patients.
